Zwei Insulin-glargin-Formulierungen im Vergleich

Mönnig, Elisabeth; Schloot, Nanette C.; Hohberg, C.; Wiesner, Tobias; Heinemann, Lutz

doi:10.1007/s15006-016-8609-y

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only two original articles reporting data from clinical trials with BioIns were published in the last year (11,12). However, some comments and reviews were published about BioIns, mainly focusing on the situation in other countries, for example, Germany (13,14) and Europe (15), or more general to the introduction of BioIns (7,16). Also, preclinical data for Abasaglar were published (17).…”

Section: Clinical Trialsmentioning

confidence: 99%

New Insulins, Biosimilars, and Insulin Therapy

Danne

Heinemann²,

Bolinder

2018

Diabetes Technology & Therapeutics

Self Cite

View full text Add to dashboard Cite

A dvances in insulin formulations continue to be important for diabetes management, but clinical safety and efficacy need to be established. Today, the increased availability of continuous glucose monitoring already allows a more intricate analysis of clinical insulin action than was previously possible. This permits an assessment of whether these new insulins provide a better means for achieving optimal glycemic control beyond HbA1c, which is increasingly receiving scientific and regulatory acceptance. This comes at a time when rapid developments in the device area, as showcased by the U.S. Food and Drug Administration (FDA) approval of the hybrid closed loop (MiniMed 670G, Medtronic) in September 2016, ask for pharmacological advances to facilitate the development of closed-loop pump systems (i.e., artificial pancreas) potentially being a treatment option for insulin-dependent patients with both type 1 and type 2 diabetes.At the same time insulin may no longer be the only treatment approved for type 1 diabetes, as sotagliflozin (Lexicon/Sanofi), a novel, oral antidiabetic agent has achieved success in several phase 3 clinical trials. Indeed, Jorge Insuasty, senior vice president and head of global development at Sanofi, announced in the summer of 2017 that they will be pursuing regulatory submissions for the adjunct treatment of type 1 diabetes worldwide, which may have a significant impact on the way we treat type 1 diabetes in the future. This year's attention focused on the first-ever next-generation mealtime insulin to be launched globally. Fiasp (NovoNordisk) is the brand name for fast-acting insulin aspart. After the ultra-fast rapid-acting insulin aspart was approved by the European Commission and other authorities early in 2017, it was launched in April in Canada, Germany, and the United Kingdom and will be coming soon to more European countries, while the FDA approval process is still ongoing. At the same time, clinicaltrials.gov lists completed phase 1 trials with Eli Lilly's new ultra-rapid insulin LY900014, which have yet to be published. In contrast, the December 2014 Collaboration Research and License Agreement between Lilly and Adocia for the development of BioChaperone Lispro, Adocia's ultra-rapid insulin for treatment in people with type 1 and type 2 diabetes, was terminated in January 2017.Regarding the long-acting analogs, the year provided evidence for their efficacy in reducing the hypoglycemia risk with the ultra-long-acting insulins Toujeo (Sanofi) and Tresiba (NovoNordisk) as well as for the cardiovascular safety of Tresiba, providing reassuring data for clinical practice.In the second year after the first biosimilar insulin (BioIns) got market approval in the European Union and the United States (not as a BioIns due to the current regulatory situation in the United States), some changes in the insulin marketplace occurred, but nothing overwhelming happened. In the United States some insurance companies switched from Lantus to Basaglar (insulin glargine by Lilly/Boehringer Ingelheim

show abstract